Oct 2, 2018

Psychotropic drug use is common in Alzheimer’s disease

Up to half of people with Alzheimer’s disease (AD) use a psychotropic drug, and one in five uses two or more psychotropics concomitantly, according to a study conducted at the University of Eastern Finland.


Psychotropic drug - use is common in Alzheimer’s disease
Psychotropic drug use was more common among persons with Alzheimer’s five years before the diagnosis, and the difference to comparison persons without AD increased at the time of diagnosis.

Four years after the diagnosis, psychotropic drug use was three times more common in persons with AD than in persons without Alzheimer's Disease.


Psychotropic drugs are frequently used for the treatment of behavioral and psychological symptoms of dementia in persons with Alzheimer's disease (AD). Evidence for benefits are limited and concerns have been raised about the safety, especially for the concomitant use of multiple psychotropic drugs.

Subscribe to the Alzheimer's Reading Room
Email:

The Gist

The objective of this study was to investigate prevalence of psychotropic drug and psychotropic polypharmacy (PPP) use and associations with PPP among persons with and without AD, from five years before until four years after AD diagnosis at time points every six months.
  • Of psychotropic drugs, the use of anti-psychotics was almost eight times more common among persons with Alzheimer’s disease than among comparison persons.

There were no differences in the use of benzodiazepines and related drugs.


The Findings

The use of at least two psychotropics concomitantly was three times more common among persons with Alzheimer’s disease four years after the diagnosis.
  •  The most common combination included an antidepressant together with either an antipsychotic or a benzodiazepine.
The use of first-line anti-dementia drugs, namely acetylcholinesterase inhibitors,
  • was associated with a decreased risk of psychotropic polypharmacy, 
  • whereas memantine use was associated with an increased risk.
“Concomitant use of psychotropics is concerning, as previous studies have shown that there is a link between several adverse events and psychotropic drug use among older persons and persons with dementia,” says Professor Sirpa Hartikainen from the University of Eastern Finland.
Guidelines of care in many countries recommend prescribing an acetylcholinesterase inhibitor to persons with Alzheimer’s disease, if there is no contraindication for use.

This study was part of the nationwide register-based MEDALZ study conducted at the University of Eastern Finland. The study included all 70,718 persons diagnosed with Alzheimer’s disease in Finland during 2005-2011. Researchers from Utrecht University also contributed to this study.

The results were published in European Neuropsychopharmacology.

Citation
Kim Orsel, Heidi Taipale, Anna-Maija Tolppanen, Marjaana Koponen, Antti Tanskanen, Jari Tiihonen, Helga Gardarsdottir, Sirpa Hartikainen. "Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease".
European Neuropsychopharmacology, 2018; DOI: 10.1016/j.euroneuro.2018.04.005


Related Articles

6 Ways to Reduce Alzheimer's Risk and Keep Your Brain Healthy As You Age

Problems with Balance, Walking, Falling Can Be an Early Sign of Dementia

The Last 25 Articles in the Alzheimer's Reading Room

Does the Combination of Aricept and Namenda Slow the Rate of Decline in Alzheimer's Patients

Light Exposure in Nursing Homes Decreases Sleep Disturbances, Depression and Agitation in Alzheimer's Patients

Sleep Medications for Alzheimer's and Dementia Patients

Alzheimer's Reading Room You Tube Channel


You are reading original content the Alzheimer's Reading Room

Did you know the Alzheimer's Reading Room contains more than 5,000 articles and has been published since July, 2009?

The website is designed to help caregivers deal with the problems they face each day.

Need Help? Search Our Award Winning Knowledge Base for Answers to Your Questions About Alzheimer's and Dementia